TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23548422
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment of CHF
Study: 21651760
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual without specific training (control condition)
Study: 19349389
Drug: Talc slurry
Normalized name: Talc
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talc slurry (TS) administered through a chest tube
Study: 16291715
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of escitalopram
Study: 16291715
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of escitalopram (single or multiple doses)
Study: 16291715
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of escitalopram
Study: 16291715
Drug: Concurrent intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent intake of food with escitalopram
Study: 10547226
Drug: CVT-1 at
Normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVT-1 at doses of 0, 300, 1500, and 3000 mg/day
Study: 10547226
Drug: CVT-1 at
Normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVT-1 at 1000 mg three times daily for 2 weeks
Study: 7799011
Drug: Eight-drugs-in-1-day chemotherapy
Normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight-drugs-in-1-day chemotherapy
Study: 288486
Drug: Lithium carbonate,
Normalized name: Lithium Carbonate, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium carbonate, 300 mg t.i.d.
Study: 31585826
Drug: Cenegermin 20
Normalized name: CENEGERMIN 20 ug in 1 mL OPHTHALMIC SOLUTION/ DROPS [OXERVATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenegermin 20 μg/ml, 6 drops daily for 8 weeks
Study: 31585826
Drug: Vehicle eye
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle eye drops, 6 drops daily for 8 weeks
Study: 19268776
Drug: Low-dose doxycycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxycycline (50 mg/d)
Study: 19268776
Drug: Medium-dose doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium-dose doxycycline (100 mg/d)
Study: 19268776
Drug: High-dose doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose doxycycline (300 mg/d)
Study: 11535972
Drug: Sildenafil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil and L-Arginine
Study: 9623550
Drug: Single-sample method
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-sample method for GFR >40 ml/min
Study: 8146789
Drug: Intravascular laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular laser blood irradiation (ILBI) with helium-neon laser, daily procedures
Study: 3292719
Drug: Vancomycin prophylaxis
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin prophylaxis (single prophylactic dose)
Study: 3292719
Drug: No antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antimicrobial agents (control group)
Study: 30547766
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mirtazapine with SNRI or SSRI antidepressants
Study: 30547766
Drug: SNRI or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNRI or SSRI therapy alone
Study: 23973689
Drug: LDL-C levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C levels <70 mg/dl
Study: 20234350
Drug: Celecoxib 16
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 16 mg/kg/day
Study: 15705084
Drug: Darifenacin 7.5
Normalized name: darifenacin 7.5 MG
DrugBank: Darifenacin (DB00496)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Darifenacin 7.5 mg
Study: 16100298
Drug: Darifenacin 15
Normalized name: darifenacin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin 15 mg
Study: 15999217
Drug: Darifenacin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin 30 mg
Study: 7795833
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of weight loss and reduced sodium intake
Study: 1781272
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for patients with increased basal and residual TR
Study: 1781272
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for patients with increased basal TR but normal residual TR
Study: 1781272
Drug: Aesthetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aesthetic treatment for patients with normal total basal resistance
Study: 25580924
Drug: Tetrabenazine (TBZ)
Normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrabenazine (TBZ) 25-150 mg/d for 6 weeks
Study: 23574533
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/day) plus nateglinide (PIO arm)
Study: 23574533
Drug: Glimepiride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (2 mg/day) plus placebo (GLI arm)
Study: 17338998
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose intravenously 200 mg once per week for 5 weeks
Study: 17338998
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate 200 mg by mouth 3 times per day for 8 weeks
Study: 15550791
Drug: Levosimendan low
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan low dose (12 microg/kg)
Study: 15550791
Drug: Levosimendan high
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan high dose (24 microg/kg)
Study: 11201872
Drug: Physical or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical or occupational therapy, reconstructive surgery, or temporary socioeconomic assistance
Study: 11201872
Drug: Trials of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trials of alternative drugs or regimens for treating neuropathy
Study: 1441872
Drug: 1% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% prilocaine (20 ml) for 3-in-1 block
Study: 1441872
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml prilocaine for 3-in-1 block
Study: 1441872
Drug: 35 ml
Normalized name: ethanol 0.35 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 ml prilocaine for 3-in-1 block
Study: 3515918
Drug: Flurbiprofen, 100
Normalized name: Flurbiprofen, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen, 100 mg twice daily
Study: 7932425
Drug: Naproxen, 250
Normalized name: Naproxen, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen, 250 mg twice daily
Study: 3515918
Drug: Flurbiprofen, 100
Normalized name: Flurbiprofen, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen, 100 mg twice daily (open-label phase)
Study: 30745885
Drug: Exenatide 2
Normalized name: exenatide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 2 mg once-weekly (n = 23)
Study: 22669847
Drug: Intravitreal pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal pegaptanib with laser therapy
Study: 27124881
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab monotherapy
Study: 9713225
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy alone
Study: 19728082
Drug: Fluvastatin high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin high dose (80 mg/day)
Study: 19728082
Drug: Fluvastatin low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin low dose (20 mg/day)
Study: 19728082
Drug: Fluvastatin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (both doses)
Study: 10516867
Drug: Verapamil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (5 mg/hour intravenously for the first 24 hours, followed by 120 mg t.i.d. perorally for 6 months)
Study: 7628095
Drug: Lecithin/sphingomyelin (L/S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecithin/sphingomyelin (L/S) ratios
Study: 2038732
Drug: Theophylline (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (twice a day)
Study: 2038732
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline (1 mg four times a day)
Study: 27189615
Drug: Cryotherapy made
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy made with chamomile infusion
Study: 24666884
Drug: tolterodine/pilocarpine (2/9
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine/pilocarpine (2/9 mg)
Study: 24666884
Drug: tolterodine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine IR 2 mg
Study: 24666884
Drug: tolterodine/pilocarpine (3/13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine/pilocarpine (3/13.5 mg)
Study: 24666884
Drug: tolterodine extended-release
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine extended-release 4 mg
Study: 21963581
Drug: Insulin multifaceted
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin multifaceted safety program
Study: 18629370
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (an angiotensin II type 1 receptor blocker)
Study: 18629370
Drug: Placebo (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (standard therapy)
Study: 12900341
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (CEE) 0.625 mg/d for 3 months
Study: 12900341
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (CEE) 0.3125 mg/d for 3 months
Study: 1281259
Drug: GHRH +
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH + porcine galanin (12.5 micrograms/min in 100 mL saline)
Study: 1281259
Drug: GHRH +
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH + saline (100 mL)
Study: 1281259
Drug: GHRH +
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH + galanin infusion
Study: 6744948
Drug: Econazole nitrate
Normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Econazole nitrate 1.0 percent cream once a day
Study: 31731677
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of health and environmental messages
Study: 28826166
Drug: Myofascial trigger
Normalized name: Anti-AML/SCCL-trigger monoclonal antibody
DrugBank: pM-81 (DB17432)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial trigger therapy (MT) combined with Cellconnect Impulse vibrotreatment
Study: 28826166
Drug: Myofascial trigger
Normalized name: Anti-AML/SCCL-trigger monoclonal antibody
DrugBank: pM-81 (DB17432)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial trigger therapy (MT)
Study: 17106839
Drug: Acute psychiatric
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute psychiatric day-hospital treatment
Study: 12214339
Drug: UDCA (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (15 mg/kg day)
Study: 9790157
Drug: Citalopram (20+/−10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20+/−10 mg/day) during luteal phase only and placebo during follicular phase (intermittent treatment)
Study: 9790157
Drug: Citalopram continuously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram continuously at a constant dosage (20+/−10 mg/day) throughout the menstrual cycle (continuous treatment)
Study: 9790157
Drug: Citalopram continuously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram continuously throughout the cycle at a lower dosage in the follicular phases (5 mg/day) than in the luteal phases (20+/−10 mg/day) (semi-intermittent treatment)
Study: 7615287
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy (n = 11)
Study: 7615287
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (n = 10)
Study: 7615287
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment (n = 13)
Study: 877819
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic povidone-iodine
Study: 877819
Drug: Infusion site
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion site examination every eight hours
Study: 877819
Drug: Infusion duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion duration
Study: 23640589
Drug: 70 ml
Normalized name: ALCOHOL 70 mL TOPICAL SWAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 ml concentrated beetroot juice (BR)
Study: 23640589
Drug: 140 ml
Normalized name: syringe, disposable, 140 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 ml concentrated beetroot juice (BR)
Study: 23640589
Drug: 280 ml
Normalized name: ALCOHOL 280 mL in 400 mL TOPICAL GEL [Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280 ml concentrated beetroot juice (BR)
Study: 2704174
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30, 50, 70 mg/d for 4 weeks
Study: 9772612
Drug: Niaodujing (NDJ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaodujing (NDJ) treatment
Study: 1656827
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (MACC: intravenous methotrexate, intravenous doxorubicin, intravenous cyclophosphamide, and oral lomustine) followed by thoracic radiotherapy
Study: 1656827
Drug: Thoracic radiation
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic radiation therapy alone (5000 cGy in 5 weeks with a 1000 cGy boost)
Study: 6408808
Drug: sulfinpyrazone (Anturan)
Normalized name: Sulfinpyrazone
DrugBank: Sulfinpyrazone (DB01138)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sulfinpyrazone (Anturan) 800 mg/die
Study: 31381152
Drug: fosnetupitant 81
Normalized name: FOSNETUPITANT
DrugBank: Fosnetupitant (DB14019)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fosnetupitant 81 mg
Study: 28776431
Drug: Internet-based cognitive-behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavior therapy with therapist support (n=20)
Study: 28776431
Drug: Internet-based cognitive-behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavior therapy without therapist support (n=22)
Study: 27838685
Drug: Personalized, spectrally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized, spectrally altered classical music therapy
Study: 24390009
Drug: Low-intensity pulsed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity pulsed ultrasound (LIPUS) for 20 minutes daily during treatment
Study: 24390009
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without LIPUS treatment
Study: 22646847
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (405 mg/4 weeks, 210 or 300 mg/2 weeks)
Study: 22646847
Drug: Oral olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral olanzapine (10 ± 2.5 or 15 ± 2.5 mg/day)
Study: 22646847
Drug: Haloperidol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (15 ± 5 mg/day)
Study: 22339430
Drug: Oral olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral olanzapine
Study: 19387396
Drug: HMB supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB supplementation (3 g/d)
Study: 18088023
Drug: Active sublingual
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active sublingual immunotherapy with SLITone grass mix plus olive pollen extract for 6 months
Study: 31324206
Drug: Penile topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penile topical metronidazole
Study: 19909586
Drug: Single-dose GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose GnRH agonist (0.5 mg leuprolide acetate) administered subcutaneously on day 6 after ICSI
Study: 19909586
Drug: Standard luteal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard luteal support (intravaginal 600 mg micronized progesterone) without GnRH agonist
Study: 19909586
Drug: Single-dose GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose GnRH agonist
Study: 16736388
Drug: Conventional antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antidepressants (CA, mainly SSRIs)
Study: 16094658
Drug: Conventional antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antidepressants (CA)
Study: 16035398
Drug: Nimesulide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide and Ibuprofen (both)
Study: 28116801
Drug: oral ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral ezetimibe 10 mg daily
Study: 23994369
Drug: 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) at 500 mg/kg
Study: 23994369
Drug: Allopurinol at
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol at 500 mg/kg
Study: 21489570
Drug: Almonds (28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonds (28 g) consumed with a standardized meal
Study: 11768838
Drug: Almotriptan 6
Normalized name: almotriptan 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 6 mg
Study: 11768838
Drug: Almotriptan 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 10 mg
Study: 29688615
Drug: Bococizumab 150
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bococizumab 150 mg subcutaneous injection via prefilled syringe (PFS) using drug substance manufactured by Pfizer
Study: 29688615
Drug: Bococizumab 150
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bococizumab 150 mg subcutaneous injection via prefilled syringe (PFS) using drug substance manufactured by Boehringer Ingelheim Pharma
Study: 29688615
Drug: Bococizumab 150
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bococizumab 150 mg subcutaneous injection via prefilled pen using drug substance manufactured by Pfizer
Study: 29688615
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (PFS by Pfizer, PFS by Boehringer Ingelheim, prefilled pen by Pfizer)
Study: 29449189
Drug: Chemoradiotherapy (radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (radiotherapy plus chemotherapy consisting of two cycles of cisplatin 50 mg/m2 during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2)
Study: 24220749
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg administered 1 h preoperatively
Study: 24220749
Drug: Placebo 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 200 mg administered 1 h preoperatively
Study: 17434845
Drug: FOTO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOTO treatment schedule (5 days on, 2 days off)
Study: 17434845
Drug: FOTO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOTO treatment schedule with efavirenz-based regimens
Study: 17434845
Drug: FOTO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOTO treatment schedule
Study: 15154088
Drug: FSH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH treatment (n=24)
Study: 12243815
Drug: 5‐fluorouracil (5‐FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU) by protracted venous infusion
Study: 2803403
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or four inhalant anti-asthmatic drugs
Study: 1125119
Drug: QX-572 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: QX-572 (8 mg/kg body weight intravenously over 30 minutes)
Study: 27129183
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg followed by 0.5 mg 1 hour later)
Study: 10341163
Drug: D-tagatose (29
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-tagatose (29 g)
Study: 10341163
Drug: Sucrose (29
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (29 g)
Study: 6793298
Drug: LNG‐containing preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG‐containing preparation